老年非小细胞肺癌患者外周血T淋巴细胞活化抗原表达的临床研究

Clinical study on the expression of lymphocyte activation antigen in peripheral blood of aged patients with non-small cell lung cancer

目的 观察老年非小细胞肺癌患者外周血T淋巴细胞活化抗原CD3+ /CD2 5 + 、CD3+ /HLA DR+ 和CD3+ /CD6 9+ 的表达。 方法 应用流式细胞双色免疫荧光标记术对 4 5例老年肺癌患者上述 3种外周血T淋巴细胞活化抗原表达进行检测 ,并与非老年肺癌组、健康老年对照组和老年良性病变组对比。 结果 4 5例老年肺癌患者外周血T淋巴细胞中CD3+ /CD2 5 + 、CD3+ /HLA DR+ 和CD3+ /CD6 9+ 表达 (分别为 7 2 4± 1 85、2 8 4 6± 5 39和 7 78± 2 6 3)低于健康老年对照组(分别为 10 35± 2 5 4、37 16± 5 5 1、11 0 2± 2 18)和良性病变组 (分别为 9 5 3± 3 0 2、35 33± 5 2 3、10 6 7± 2 4 5 ) ,P <0 0 1。老年组与非老年组表达水平比较差异有显著性 (P <0 0 5或P <0 0 1)。对照组和老年良性病变组之间差异无显著性 (P >0 0 5 )。Ⅲ、Ⅳ期 (分别为 7 15± 1 13、2 5 32±5 2 3、7 14± 2 81)和Ⅰ、Ⅱ期 (分别为 8 0 6± 1 2 1、30 2 7± 6 0 5、8 4 3± 2 6 7)表达比较 ,差异有显著性 (P <0 0 1)。中、高分化程度的肺癌患者其表达 (分别为 8 2 3± 1 2 3、34 0 5± 6 6 1、11 2 5± 3 2 2 )明显高于低分化程度的肺癌 (分别为 7 0 2± 1 35、2 5 31± 5 87、5 31± 3 5 7) ,P <0

Objective To analyze the expression of T lymphocyte activation antigen in peripheral blood of aged patients with non-small cell lung cancer . Methods The lymphocytes from peripheral blood in 45 aged patients with non-small cell lung cancer were immunologically labeled in double fluorescence and CD3-FITC, CD25/HLA-DR and CD69-PE and determined by flow cytometry. Normal aged donors, young patiens with lung cancer and aged benign lesion group were used as controls. Results Peripheral blood CD3 +/CD25 +, CD3 +/HLA -DR + and CD3 +/CD69 + in T lymphocyte with 45 aged lung cancer(7.24±1.85,28.46±5.39 and 7.78±2.63, respectively) were significantly lower than those in normal aged controls(10.35±2.54,37.16±5.51,11.02±2.18, respectively)and aged benign lesion (9.53±3.02, 35.33±5.23, 10.67±2.45, respectively)( P <0.01). The expression of them in aged lung cancer patients was also lower than those in young lung cancer patients ( P <0.05 or P <0.01). There was no significantly statistic differences between normal aged controls and aged benign lesion ( P >0.05). Significant differences were found among them in stages Ⅲ, Ⅳ(7.15±1.13, 25.32±5.23, 7.14±2.81, respectively) and stagesⅠ,Ⅱ(8.06±1.21, 30.27±6.05, 8.43±2.67, respectively)( P <0.01). The expression of them in moderately differentiated cancer groups(8.23±1.23, 34.05±6.61 and 11.25±3.22, respectively)were significantly higher than those in poorly differentiated groups(7.02±1.35, 25.31±5.87, 5.31±3.57, respectively) ( P <0.01 ). The expression of them were not correlated with the pathological types( P >0.05). Conclusions Detection of CD3 +/CD25 +, CD3 +/HLA -DR + and CD3 +/CD69 + levels by flow cytometry might be helpful for reflecting the human immune function and the prognosis evaluation in patients with aged non-small cell lung cancer.